Peginterferon Alfa-2a and Ribavirin for 24 Weeks in Hepatitis C Type 1 and 4 Patients With Rapid Virological Response
Top Cited Papers
- 31 August 2008
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 135 (2) , 451-458
- https://doi.org/10.1053/j.gastro.2008.04.015
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic responseHepatology, 2007
- Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patientsHepatology, 2007
- Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapyHepatology, 2006
- Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus RibavirinGastroenterology, 2006
- American Gastroenterological Association Medical Position Statement on the Management of Hepatitis CGastroenterology, 2006
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirinJournal of Hepatology, 2005
- Diagnosis, management, and treatment of hepatitis C†Hepatology, 2004
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialPublished by Elsevier ,2001